Movement matters for kidney health. But for many people, moving more can feel overwhelming. That is why even small conversations in routine care can make a real difference.
Emerging evidence suggests that activities such as walking, stair climbing and resistance exercise are all associated with lower mortality risk. The message is simple: everyday movement counts.
Start the conversation with your patients today and spread the message with our “Protect Your Kidneys, Protect Your Future” Social Media Ambassador Toolkit 👉 https://t.co/VTodJ64CQv
#StrongKidneys #KidneyHealth #MoveForYourKidneys #CKDPrevention #ProtectYourKidneys
🤖 Will AI replace nephrologists?
💡In this 77th episode of A pinch of salt, Hugo Diniz sits down with Wisit Cheungpasitporn @wisit661 to demystify what generative AI can actually do, expose what it definitely can't (yet), and make it approachable for every working nephrologist.
🎧 Hit play now 👉 https://t.co/5jw2g95C1j
🔎 Discover the most read and most cited articles published in Clinical Kidney Journal over the past 12 months.
👏 Thank you to the authors and peer reviewers whose contributions continue to advance kidney research and care.
Discover more 👉 https://t.co/c3mC4vDzRh
En choque séptico y vasopresores, la hemoadsorción con cartucho HA-330 (Jafron), comparado a lo habitual; no mejoró mortalidad, ni tampoco alguno de los objetivos secundarios relevantes
Otro fracaso de hemoadsorción
Ensayo clínico CLEANSE
Critical Care 2026
https://t.co/ilTfpYn2k1
🌟 Beyond the Congress: A partnership between ERA and Glasgow Children's Hospital Charity @FriendsofGRI
🤝 ERA is proud to partner with Glasgow Children's Hospital Charity, helping create an impact that reaches far beyond the Congress
📹 Watch the video to discover more about this meaningful partnership
🔴 Chronic kidney disease (CKD) affects millions of people worldwide and often progresses silently.
⌛ With one person dying from the disease every 20 seconds, increasing awareness of CKD remains essential.
🎥 Watch the video to learn more about CKD, its challenges, and the importance of early diagnosis.
🎉 Congratulations to Stefka Kostyaneva who received the 2026 ERA National Grant during the Annual Conference of the Bulgarian Nephrology Association.
🏆 National Societies can award young nephrologists who submit an Abstract with an ERA National Grant.
📌 Ask your National Society for more info!
🎉 We’re delighted to share the latest Impact Factors and CiteScores for our leading nephrology journals Nephrology Dialysis Transplantation (NDT) and Clinical Kidney Journal (CKJ).
🙏 Our heartfelt gratitude goes to the exceptional contributions of our authors, reviewers, readers, and editorial board.
El viernes y el sábado celebramos la XX #ReuniónSOMANE 🏥
El Dr. José Luis Merino, presidente de la Sociedad Madrileña de Nefrología, se marcaba estos objetivos para el congreso 🩺
#SOMANE#Nefrología
🧵1/10 Obesity in CKD - part III/III
This #ERA26 symposium challenged us to think beyond weight loss &BMI ⚖️, and also to reflect on the impact of the increasing 🌍 consumption of Ultraprocessed Foods (UPFs)🍔🍟🥤.
#ChallengeYourThinking #CKD #Obesity
🪑 Ziad Massy @MassyZiad
🪑 Inga Arune Bumblyte
2/ #ERA26
💉High-dose influenza vaccines generate stronger and more durable antibody responses in hemodialysis patients
🔎FLUNITY-HD pooled data from DANFLU-2 (332k) and GALFLU (134k) to assess severe outcomes
🔥Next at #ERA26 Emerging Trial Evidence in Hypertension, CKD, and Transplantation
Moderated
⏩ EKFC outperforms CKD-EPI 2009 and 2021 in Kidney Transplant Recipients when Compared to Iohexol Serum Clearance (mGFR) – a National Cohort Study
🎙️Presented by Ingrid Charlotte Kongerud
🔎EKFC was compared with CKD-EPI 2009/2021 against iohexol-measured GFR
🎯Goal: identify the most accurate eGFR equation in transplant recipients
Happening in Clyde now at #ERA26
Prediction, precision and inclusion in ANCA vasculitis: open your mind to new possibilities
Gender disparity and sex disaggregated outcomes in ANCA vasculitis: should we rethink?
🗣️Vanja Ivkovic
#ERA2026
💡Interesting work comparing HV-HDF and HDx using different β2-microglobulin clearance metrics.
✅As expected, HV-HDF achieved higher β2M clearance.
✅The novel aspect was the evaluation of eCDCβ2M, an equivalent continuous clearance metric that may better reflect middle-molecule kinetics than traditional reduction ratios or urea-derived measures.
The next challenge: proving that these metrics predict clinical outcomes, not just toxin removal.
#Nephrology #Dialysis #HDF #HDx
Extracellular Vesicles in Transplant & Kidney Disease | #ERA26
Extracellular vesicles are released from all cells. They play roles in antigen presentation, immune regulation, and metabolic signaling.
Biology & Measurement
Can be measured in blood but not in urine
Appear after ischemia and are linked to ferroptosis, a type of cell death
Involved in both induction of immune response and induction of immune tolerance
Role in Transplant Rejection
Donor-derived extracellular vesicles cause B cell activation and donor specific antibody production
Complement system activation has been shown through extracellular vesicles
In acute kidney injury of the graft, aquaporin 2 release has been demonstrated via extracellular vesicles
Complement activation can be detected using extracellular vesicles
Role in Autoimmune Kidney Disease
Carry autoantigen-antibody complexes in autoimmune kidney diseases
Associated with glomerulosclerosis
Takeaway: Extracellular vesicles act as messengers between cells in transplant rejection and kidney disease. They link immune activation, complement activation, and tissue injury. Potential biomarkers and therapeutic targets.
Presentation: Fabian Braun | Tweet: @eroldemir83 on behalf of SoMe Team
From #ERA26 FC22, Partha Das and the DaVita International team present a large matched multinational cohort from Latin America and the Middle East: does online HDF reduce mortality and hospitalisation compared with HD? #ERAkidney#Dialysis
Late breaking trials 2
Efficacy, safety and pharmacokinetics/pharmacodynamics of crovalimab for paediatric atypical haemolytic uraemic syndrome: Phase III COMMUTE-p trial
By Maria Helena Vaisbich
#ERA26